Atlas Trials

Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) in Resectable Pancreatic Adenocarcinoma: Randomized Phase II Trial

Clinical trial NCT06816914 · RECRUITING

Trial details

NCT number
NCT06816914
Sponsor
Taichung Veterans General Hospital
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Resectable Pancreatic Adenocarcinoma
Start date
2025-03-05
Primary completion
2027-02-05
Enrollment
84

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.